Please login to the form below

Not currently logged in

People, November, 2011

Recent high-profile moves in the pharmaceutical and healthcare industriesMover of the month is Kenneth C Frazier who replaces Richard T Clark as chair of Merck

Mover of the month


Richard T Clark (right), chair of Merck (known as MSD outside the US and Canada) retires on December 1, 2011. He will be replaced by current CEO, Kenneth C Frazier, who was elected by the board of directors. Clark joined Merck in 1972 as a quality control inspector and became chair in 2010. Other roles at the company have included president and CEO from 2005 to 2010, senior vice president of quality and commercial affairs and president of the manufacturing division. He said: “I have been a part of Merck for more than 39 years – I always have and always will consider Merck to be an important part of my life and my extended family.” As CEO, Clark oversaw the launches of HIV treatment Isentress (raltegravir) and the HPV vaccine Gardasil. He also led the company's $49bn merger with Schering-Plough in 2009. 


David Meeker has been made CEO of Genzyme, which was bought by Sanofi earlier in 2011, effective from November 1, 2011. Meeker will report to Christopher A Viehbacher, CEO of Sanofi, and joins the group management committee. Viehbacher remains chairman of Genzyme. Under Meeker's leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise. Meeker joined Genzyme in 1994 and was promoted to COO in 2009.




Bristol-Myers Squibb (BMS) has made changes to its senior management team. Giovanni Caforio has been promoted to president, US pharmaceuticals. Caforio was previously senior vice president, oncology and immunology global commercialisation. Charles Bancroft and Béatrice Cazala have been appointed executive vice presidents of BMS. Bancroft will add operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim to his role of CFO. Cazala takes responsibility for global policy alongside her role leading global commercialisation, Europe and emerging markets

Nycomed, which was taken over by Takeda in September 2011, has announced that Jostein Davidsen has been appointed head of emerging markets in addition to his current role as area head of Russia/CIS. He will report to Frank Morich, EVP, international operations (Americas/Europe), Takeda Pharmaceuticals International, and CEO of Nycomed. Davidsen has been leading the legacy Nycomed Russia/CIS area since 1994.



The European Generic medicines Association's (EGA) board has elected Gudbjorg Edda Eggertsdottir as its new president. She has been active in the generic medicines industry for over 30 years, with significant experience in the generic medicines sector in companies such as Actavis, where she is president Iceland, strategic projects, and Delta. She has been on the EGA executive board for two years.

Eli Lilly is making key appointments due to the December 31 retirements of Bryce D Carmine and Frank Deane. Carmine led Lilly Bio-Medicines and Deane led global manufacturing operations. From January 1, Dave Ricks, president of Lilly USA, becomes senior vice president and president of Lilly Bio-Medicines. Previously he was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities include the US, Japan and Europe. Maria Crowe, senior vice president for global drug product manufacturing, succeeds Deane as president of manufacturing operations. Alex Azar becomes president of Lilly USA.

CEO of Shire, Angus Russell, has joined the board of InterMune, Inc. as a non-executive director, with effect from October 31, 2011.

Amgen has appointed Anthony (Tony) Hooper as executive vice president, global commercial operations. It has also appointed Robert A Bradway to the board of directors. Hooper will report to Bradway, who is president and COO. Hooper joins after 16 years at Bristol-Myers Squibb (BMS) where he was most recently senior vice president, commercial operations and president, US, Japan and intercontinental. Bradway joined Amgen in 2006 as vice president, operations strategy, and served as executive vice president and chief financial officer from 2007 to 2010. 

Ralf Huss, previously global head of the Therapeutic Cell Initiative at Roche, has joined the management board of German-based Apceth. He is a Professor of Pathology and Adjunct Professor for Regenerative Medicine at Wake Forest Institute for Regenerative Medicine in Winston-Salem in the US.

Current president of generics firm, Mylan, Heather Bresch is set to become CEO, taking over from Robert Coury, who remains as executive chairman. Mylan COO Rajiv Malik, who joined the company with its buyout of Matrix Laboratories, takes Bresch's current job. Bresch was appointed to the board in March 2011.

France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors. Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems and will chair the clinical advisory board. He has over 20 years' experience in the pharmaceutical industry at senior management level with the Sanofi Group  and the French pharmaceutical company Fournier. 

Dr Angelika Bodenteich has been appointed head of development at Austrian company Marinomed Biotechnologie, which develops innovative therapies for respiratory diseases. She joins from Onepharm Research & Development and has more than 15 years of experience in the pharmaceutical industry. She is a trained pathologist who has worked in Austria, Norway and the US.

Medical technology industry organisation Eucomed has elected a new board of directors. Guy Lebeau (Johnson & Johnson) remains chairman, Roy Bridges (BD) remains vice-chair and Roland Pfleger (Covidien) joins Roy Bridges as vice-chair. Thierry Sarda (Smith & Nephew) remains treasurer. In addition to the three sector groups already represented, community care now has a seat on the board, represented by Klaus Grunau (Hollister). There are four other new members: Jose Calle Gordo (Abbott Vascular); Anna Lefevre Skjöldebrand (Swedish Medtech and
chair of the National Associations Network); Donald Munro (Rayner Intraocular Lenses) and Renaat Vermeulen (Biomet). 

The Drug Information Association (DIA) has appointed Kaushik Desai as director of DIA India. He has a deep knowledge of the global regulatory framework and the pharmaceutical environment in India and is a trained pharmacist.

Related links

FAQ: How do I get my move listed


Subscribe to our email news alerts

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research